ストックスクリーナーアプリを入手
62.35
1.43%
0.88
アフターアワーズ：
62.41
0.06
+0.10%
Monopar Therapeutics Inc (MNPR) 最新ニュース
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade - Zacks Investment Research
Monopar Therapeutics Q1 2026 Earnings: Smaller-than-Expected Loss as EPS Surprises PositivelyRevenue Report - newsline.com
Understanding Momentum Shifts in (MNPR) - Stock Traders Daily
Monopar Therapeutics (MNPR) Climbs Nearly 2%, Approaches Key Resistance at $63.64Inside Day Breakout - newsline.com
Piper Sandler Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $101 - Moomoo
Monopar Therapeutics stock declines as late-session selling erases earlier gains - Traders Union
Monopar: Buy Rating Reiterated as ALXN1840 Data Underpin Valuation and $104 Price Target Maintained - TipRanks
Lake Street Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR) - The Globe and Mail
A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $101 to $105 - Moomoo
MNPR Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineFinal Results - newsline.com
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - ChartMill
Monopar Therapeutics (MNPR) Showcases Promising Phase 2 Results at EASL Congress 2026 - GuruFocus
Monopar presents phase 2 data on Wilson disease treatment - Investing.com UK
Monopar Therapeutics Presents Phase 2 Data for ALXN1840 at EASL Congress 2026, Demonstrating Liver Disease Stabilization and Neurological Improvements in Wilson Disease Patients - Quiver Quantitative
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 - GlobeNewswire Inc.
Monopar Therapeutics Presents Phase 2 Results of ALXN1840 (Tiomolibdate Choline) for Wilson Disease at EASL International Liver Congress 2026 7 - Minichart
MNPR Q1 2026 Earnings: Loss Narrower Than Expected, Stock Rises on Positive SurpriseEarnings Recovery Stocks - newsline.com
MNPR Q1 2026 Earnings: Narrower-than-expected loss as early-stage biotech advances radiopharmaceutical pipelineRevenue Report - newsline.com
Avoiding Lag: Real-Time Signals in (MNPR) Movement - Stock Traders Daily
Monopar Highlights Phase 2 ALXN1840 Data in Wilson Disease - TipRanks
Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026 - Stock Titan
Monopar Therapeutics shares dip amid rising selling pressure - Traders Union
Monopar Therapeutics (MNPR) Holds Steady at $64.43: Slight Decline Signals ConsolidationLast Point Resistance - The Legal Advocate
What triggered Monopar Therapeutics shares' latest price surge - Traders Union
Monopar Therapeutics stock rises as short-term exhaustion signals surface after recent rally - Traders Union
Why is Monopar Therapeutics stock up today? - Traders Union
What triggered Monopar Therapeutics shares' latest price pullback - Traders Union
Monopar Therapeutics (MNPR) News Today: Latest Market and Industry Updates - Traders Union
Monopar Therapeutics stock price forecast: Holding $60.25 support as MNPR declines 2.47% - Traders Union
Monopar Therapeutics Q1 2026 Earnings: Narrower Loss Surprises MarketEarnings Outlook Update - Newser
MNPR Q1 2026 Earnings: Surprise EPS Beat in Pre-Revenue BiotechRevenue Inflection Point - The Legal Advocate
Monopar Therapeutics Presents Positive Phase 2 Results for ALXN1840 in Wilson Disease Patients - Minichart
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease - The Manila Times
Monopar reports positive Wilson disease trial data publication By Investing.com - Investing.com South Africa
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data - TipRanks
Monopar reports positive Wilson disease trial data publication - Investing.com India
Monopar Therapeutics Publishes Phase 2 Trial Results of ALXN1840 for Wilson Disease in Hepatology Communications - Quiver Quantitative
Monopar Therapeutics Inc Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease - marketscreener.com
ALXN1840 Wilson disease trial data published by Monopar (NASDAQ: MNPR) - Stock Titan
Chardan Capital Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Cuts Target Price to $59.27 - Moomoo
MNPR SEC FilingsMonopar Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Leerink Partners Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Saturn V, Xiaoying Tian report 345,626 MNPR shares (5.20%) — MNPR - Stock Titan
Monopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged - TipRanks
A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $104 to $130 - Moomoo
Is Monopar Therapeutics (MNPR) Undervalued After Q1 2026 EPS Bea - GuruFocus
Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Monopar Therapeutics reports Q1 2026 loss, advances ALXN1840 NDA submission for Wilson disease. - Pluang
Monopar Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Monopar (NASDAQ: MNPR) ends Q1 with $137.5M cash and funds through 2027 - Stock Titan
Monopar Therapeutics 1Q 2026: Revenue ($3.93M), Net income ($3.89M), EPS ($0.46) — 10-Q Summary - TradingView
Monopar Therapeutics Reports Q1 2026 Financial Results and Updates on ALXN1840 Development for Wilson Disease - Quiver Quantitative
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Monopar Therapeutics reports Q1 2026 net loss $3.9M, cash $137.5M; NDA on track for mid-2026 - TradingView
Cash runway to 2027 as Monopar (NASDAQ: MNPR) readies ALXN1840 - Stock Titan
Press Release: Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - Moomoo
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):